Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Vertex Pharmaceuticals	Takeda Pharmaceutical	Bayer Aktiengesellschaft	Regeneron Pharmaceuticals	Alexion Pharmaceuticals
Symbol	NASDAQ:VRTX	NYSE:TAK	OTCMKTS:BAYRY	NASDAQ:REGN	NASDAQ:ALXN
Price Information
Current Price	$185.09	$17.15	$13.74	$646.51	$182.50
50-Day Moving Average	$195.78	$16.81	$14.13	$630.67	$182.82
52-Week Low	$182.60	$15.30	$11.65	$441.00	$99.91
52-Week High	$280.99	$19.97	$17.34	$686.62	$187.45
MarketRank™
Overall Score	2.8	1.7	2.3	2.5	1.9
Analysis Score	4.3	0.0	3.3	2.4	1.1
Community Score	5.0	3.9	4.3	4.5	5.0
Dividend Score	0.0	3.3	2.5	0.0	0.0
Ownership Score	3.3	0.0	0.0	3.3	1.7
Earnings & Valuation Score	1.3	1.3	1.3	2.5	1.9
Analyst Ratings
Consensus Recommendation	Buy	Hold	Buy	Buy	Hold
Consensus Price Target	$266.61	N/A	$60.00	$700.69	$161.93
% Upside from Price Target	44.04% upside	N/A	336.68% upside	8.38% upside	-11.27% downside
Trade Information
Market Cap	$48.02 billion	$54.27 billion	$53.99 billion	$69.15 billion	$40.34 billion
Beta	0.63	1.05	1.27	0.16	1.25
Average Volume	2,019,542	2,683,875	451,363	863,951	3,309,941
Sales & Book Value
Annual Revenue	$6.21 billion	$30.17 billion	$47.29 billion	$8.50 billion	$6.07 billion
Price / Sales	7.74	1.80	1.14	8.14	6.65
Cashflow	$9.40 per share	$3.68 per share	$5.77 per share	$33.19 per share	$22.81 per share
Price / Cash	19.70	4.66	2.38	19.48	8.00
Book Value	$33.41 per share	$15.42 per share	$8.92 per share	$102.91 per share	$53.24 per share
Price / Book	5.54	1.11	1.54	6.28	3.43
Profitability
Net Income	$2.71 billion	$3.53 billion	$-11,988,440,000.00	$3.51 billion	$603.40 million
EPS	$9.03	$1.98	$1.82	$28.66	$11.60
Trailing P/E Ratio	24.42	11.75	N/A	11.61	59.64
Forward P/E Ratio	16.24	18.24	6.80	14.66	13.15
P/E Growth	1.77	N/A	3.32	0.77	0.93
Net Margins	29.80%	14.69%	-6.30%	50.11%	10.89%
Return on Equity (ROE)	29.73%	13.00%	19.76%	50.43%	23.43%
Return on Assets (ROA)	21.96%	5.11%	5.37%	33.56%	15.06%
Dividend
Annual Payout	N/A	$0.68	$0.41	N/A	N/A
Dividend Yield	N/A	3.97%	2.98%	N/A	N/A
Three-Year Dividend Growth	N/A	6.41%	N/A	N/A	N/A
Payout Ratio	N/A	34.34%	22.53%	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.06%	0.83%	1.20%	0.13%	0.19%
Current Ratio	4.61%	1.51%	1.16%	3.57%	4.52%
Quick Ratio	4.43%	1.03%	0.80%	3.04%	3.96%
Ownership Information
Institutional Ownership Percentage	88.63%	2.99%	0.11%	82.31%	82.94%
Insider Ownership Percentage	0.70%	N/A	N/A	11.84%	4.03%
Miscellaneous
Employees	3,400	2,021	99,538	9,123	3,837
Shares Outstanding	259.43 million	3.16 billion	3.93 billion	106.96 million	221.02 million
Next Earnings Date	11/4/2021 (Estimated)	11/4/2021 (Estimated)	11/2/2021 (Estimated)	11/4/2021 (Estimated)	N/A
Optionable	Optionable	Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Alexion Must Face Claims Of Stalling On Drug After Merger law360.com - September 3 at 1:31 AM
	AZ/Alexion’s Wilson disease drug hits the mark in phase III, calming post-merger nerves bioworld.com - August 27 at 9:13 AM
	Ascendis’ weekly GHD treatment wins FDA go-ahead bioworld.com - August 27 at 3:52 AM
	ALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvement miragenews.com - August 26 at 7:08 AM
	Were Hedge Funds Right About Alexion Pharmaceuticals, Inc. (ALXN)? finance.yahoo.com - August 9 at 2:07 PM
	Alexion Pharmaceuticals Inc ALXN-MX cnbc.com - July 24 at 10:08 PM
	AstraZeneca Wraps Its Massive Alexion Buyout — Is AZN Stock A Buy Or Sell? finance.yahoo.com - July 23 at 3:38 PM
	Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy? finance.yahoo.com - July 22 at 5:32 PM
	ALXN vs. TECH: Which Stock Is the Better Value Option? finance.yahoo.com - July 21 at 3:06 PM
	Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) – Experts See The Stock A Different Way Today marketingsentinel.com - July 20 at 6:09 PM
	Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms feeds.benzinga.com - July 20 at 3:16 PM
	Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance msn.com - July 20 at 1:07 PM
	Alexion Pharmaceuticals Inc. [ALXN] is 14.86% higher this YTD. Is it still time to buy? dbtnews.com - July 20 at 1:07 PM
	Alexion Pharmaceuticals Stock Appears To Be Modestly Overvalued gurufocus.com - July 17 at 3:36 PM
	Moderna Options Traders Mixed On S&P 500 Inclusion msn.com - July 16 at 7:13 PM
	When Will Moderna Be Added to the S&P 500? msn.com - July 16 at 1:48 PM
	Alexion's Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness Disorder finance.yahoo.com - July 16 at 1:48 PM
	Moderna Jumps on Joining the S&P 500: What to Watch When the Stock Market Opens Today wsj.com - July 16 at 8:22 AM
	Alexion Announces Phase 3 Study Of ULTOMIRIS In Generalized Myasthenia Gravis Met Its Primary Endpoint benzinga.com - July 15 at 10:04 PM
	Moderna set to join S&P 500, stock rallies 8% msn.com - July 15 at 10:04 PM
	Moderna to join S&P 500, shares jump after hours msn.com - July 15 at 10:04 PM
	Moderna To Replace Alexion Pharma In S&P 500 markets.businessinsider.com - July 15 at 10:04 PM
	Moderna Set to Join S&P 500 markets.businessinsider.com - July 15 at 7:15 PM
	Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG) finance.yahoo.com - July 15 at 5:03 PM
	Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term finance.yahoo.com - July 15 at 12:03 PM

Date	Company	Brokerage	Action
9/21/2021	Regeneron Pharmaceuticals	BMO Capital Markets	Boost Price Target
9/15/2021	Regeneron Pharmaceuticals	Piper Sandler	Boost Price Target
9/15/2021	Regeneron Pharmaceuticals	Cantor Fitzgerald	Boost Price Target
9/15/2021	Regeneron Pharmaceuticals	HC Wainwright	Boost Price Target
9/9/2021	Vertex Pharmaceuticals	Stifel Nicolaus	Downgrade
9/9/2021	Regeneron Pharmaceuticals	UBS Group	Initiated Coverage
9/7/2021	Vertex Pharmaceuticals	Morgan Stanley	Downgrade
9/7/2021	Regeneron Pharmaceuticals	Morgan Stanley	Boost Price Target
8/23/2021	Regeneron Pharmaceuticals	Benchmark	Boost Price Target
8/20/2021	Regeneron Pharmaceuticals	HC Wainwright	Reiterated Rating
8/9/2021	Bayer Aktiengesellschaft	Berenberg Bank	Lower Price Target
8/6/2021	Bayer Aktiengesellschaft	Credit Suisse Group	Reiterated Rating
8/6/2021	Regeneron Pharmaceuticals	Barclays	Boost Price Target
8/6/2021	Regeneron Pharmaceuticals	SVB Leerink	Boost Price Target
8/6/2021	Regeneron Pharmaceuticals	BMO Capital Markets	Boost Price Target
8/6/2021	Regeneron Pharmaceuticals	Oppenheimer	Boost Price Target
8/5/2021	Regeneron Pharmaceuticals	Piper Sandler	Boost Price Target
8/4/2021	Bayer Aktiengesellschaft	AlphaValue	Downgrade
8/2/2021	Regeneron Pharmaceuticals	HC Wainwright	Boost Price Target
7/30/2021	Vertex Pharmaceuticals	Morgan Stanley	Lower Price Target
7/30/2021	Vertex Pharmaceuticals	Royal Bank of Canada	Boost Price Target
7/30/2021	Vertex Pharmaceuticals	SVB Leerink	Boost Price Target
7/30/2021	Vertex Pharmaceuticals	Piper Sandler	Boost Price Target
7/23/2021	Regeneron Pharmaceuticals	Royal Bank of Canada	Boost Price Target
7/20/2021	Vertex Pharmaceuticals	SVB Leerink	Downgrade
7/19/2021	Vertex Pharmaceuticals	Wolfe Research	Initiated Coverage
7/8/2021	Regeneron Pharmaceuticals	Benchmark	Boost Price Target
6/30/2021	Vertex Pharmaceuticals	Raymond James	Initiated Coverage
6/29/2021	Regeneron Pharmaceuticals	HC Wainwright	Initiated Coverage
6/25/2021	Bayer Aktiengesellschaft	Kepler Capital Markets	Reiterated Rating
6/14/2021	Vertex Pharmaceuticals	Truist	Boost Price Target
6/14/2021	Vertex Pharmaceuticals	Piper Sandler	Lower Price Target
6/14/2021	Vertex Pharmaceuticals	Truist Securities	Boost Price Target
6/14/2021	Vertex Pharmaceuticals	SVB Leerink	Lower Price Target
6/13/2021	Vertex Pharmaceuticals	Evercore ISI	Reiterated Rating
6/11/2021	Vertex Pharmaceuticals	Stifel Nicolaus	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	The Goldman Sachs Group	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Barclays	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Cantor Fitzgerald	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Morgan Stanley	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Robert W. Baird	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Royal Bank of Canada	Lower Price Target
6/11/2021	Vertex Pharmaceuticals	Daiwa Capital Markets	Downgrade
5/26/2021	Bayer Aktiengesellschaft	DZ Bank	Reiterated Rating
5/19/2021	Bayer Aktiengesellschaft	Morgan Stanley	Reiterated Rating
5/18/2021	Bayer Aktiengesellschaft	JPMorgan Chase & Co.	Upgrade
5/14/2021	Bayer Aktiengesellschaft	DZ Bank	Reiterated Rating
5/13/2021	Bayer Aktiengesellschaft	Credit Suisse Group	Reiterated Rating
5/13/2021	Bayer Aktiengesellschaft	Bryan, Garnier & Co	Upgrade
5/7/2021	Regeneron Pharmaceuticals	SVB Leerink	Lower Price Target
5/7/2021	Regeneron Pharmaceuticals	Morgan Stanley	Boost Price Target
5/5/2021	Alexion Pharmaceuticals	Oppenheimer	Upgrade
5/3/2021	Vertex Pharmaceuticals	Morgan Stanley	Boost Price Target
5/3/2021	Alexion Pharmaceuticals	SVB Leerink	Boost Price Target
4/26/2021	Vertex Pharmaceuticals	Morgan Stanley	Boost Price Target
4/26/2021	Alexion Pharmaceuticals	Credit Suisse Group	Initiated Coverage
4/19/2021	Vertex Pharmaceuticals	Morgan Stanley	Boost Price Target
4/19/2021	Takeda Pharmaceutical	JPMorgan Chase & Co.	Downgrade
4/19/2021	Regeneron Pharmaceuticals	Morgan Stanley	Lower Price Target
4/13/2021	Regeneron Pharmaceuticals	Robert W. Baird	Reiterated Rating
4/13/2021	Regeneron Pharmaceuticals	Canaccord Genuity	Reiterated Rating
4/5/2021	Takeda Pharmaceutical	Jefferies Financial Group	Downgrade
3/30/2021	Bayer Aktiengesellschaft	DZ Bank	Reiterated Rating
3/29/2021	Alexion Pharmaceuticals	SVB Leerink	Reiterated Rating
3/26/2021	Regeneron Pharmaceuticals	SVB Leerink	Boost Price Target
3/24/2021	Regeneron Pharmaceuticals	Canaccord Genuity	Reiterated Rating
3/23/2021	Alexion Pharmaceuticals	SVB Leerink	Downgrade
3/19/2021	Bayer Aktiengesellschaft	Deutsche Bank Aktiengesellschaft	Reiterated Rating
3/11/2021	Bayer Aktiengesellschaft	Societe Generale	Reiterated Rating
3/4/2021	Bayer Aktiengesellschaft	Berenberg Bank	Reiterated Rating
3/1/2021	Bayer Aktiengesellschaft	Morgan Stanley	Reiterated Rating
3/1/2021	Bayer Aktiengesellschaft	DZ Bank	Reiterated Rating
2/26/2021	Bayer Aktiengesellschaft	Credit Suisse Group	Reiterated Rating
2/24/2021	Regeneron Pharmaceuticals	Canaccord Genuity	Reiterated Rating
2/10/2021	Bayer Aktiengesellschaft	Barclays	Reiterated Rating
2/5/2021	Alexion Pharmaceuticals	SVB Leerink	Lower Price Target
2/4/2021	Bayer Aktiengesellschaft	DZ Bank	Reiterated Rating
2/4/2021	Alexion Pharmaceuticals	Piper Sandler	Downgrade
1/27/2021	Bayer Aktiengesellschaft	Deutsche Bank Aktiengesellschaft	Reiterated Rating
1/20/2021	Bayer Aktiengesellschaft	Credit Suisse Group	Reiterated Rating
1/8/2021	Bayer Aktiengesellschaft	Morgan Stanley	Reiterated Rating
1/8/2021	Alexion Pharmaceuticals	Raymond James	Downgrade
1/6/2021	Bayer Aktiengesellschaft	Nord/LB	Reiterated Rating
12/16/2020	Alexion Pharmaceuticals	Truist	Downgrade
12/15/2020	Alexion Pharmaceuticals	Smith Barney Citigroup	Downgrade
12/15/2020	Alexion Pharmaceuticals	Roth Capital	Boost Price Target
12/14/2020	Alexion Pharmaceuticals	SVB Leerink	Boost Price Target
12/14/2020	Alexion Pharmaceuticals	Robert W. Baird	Downgrade
12/14/2020	Alexion Pharmaceuticals	Wedbush	Downgrade
12/14/2020	Alexion Pharmaceuticals	Royal Bank of Canada	Boost Price Target
12/14/2020	Alexion Pharmaceuticals	BMO Capital Markets	Downgrade
12/14/2020	Alexion Pharmaceuticals	Credit Suisse Group	Downgrade
11/19/2020	Alexion Pharmaceuticals	Sanford C. Bernstein	Initiated Coverage
11/6/2020	Bayer Aktiengesellschaft	Morgan Stanley	Reiterated Rating
11/5/2020	Bayer Aktiengesellschaft	Deutsche Bank Aktiengesellschaft	Reiterated Rating
11/5/2020	Alexion Pharmaceuticals	Smith Barney Citigroup	Boost Price Target
11/5/2020	Alexion Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
10/30/2020	Alexion Pharmaceuticals	Svb Leerink	Lower Price Target
10/30/2020	Alexion Pharmaceuticals	SVB Leerink	Boost Price Target
10/30/2020	Alexion Pharmaceuticals	Morgan Stanley	Lower Price Target
10/29/2020	Alexion Pharmaceuticals	Piper Sandler	Boost Price Target
10/28/2020	Alexion Pharmaceuticals	UBS Group	Initiated Coverage
3/11/2020	Takeda Pharmaceutical	JPMorgan Chase & Co.	Lower Price Target
11/1/2019	Takeda Pharmaceutical	Cowen	Initiated Coverage
9/24/2019	Takeda Pharmaceutical	Jefferies Financial Group	Initiated Coverage
8/15/2019	Takeda Pharmaceutical	Daiwa Capital Markets	Downgrade
3/19/2019	Takeda Pharmaceutical	The Goldman Sachs Group	Reiterated Rating

(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources